13 results
8-K
EX-10.1
RNXT
RenovoRx Inc
14 Mar 24
Departure of Directors or Certain Officers
4:53pm
, and our mission. The Chief Clinical Officer is expected to be a people-oriented leader who leads with empathy and humility. While we are still a small
8-K
EX-99.1
RNXT
RenovoRx Inc
14 Nov 23
RenovoRx Reports Third Quarter 2023 Financial Results and Operational Highlights
12:00am
for the third quarter ended September 30, 2023.
“We remain focused on our core mission to improve the lives of patients diagnosed with difficult-to-treat
424B3
RNXT
RenovoRx Inc
19 May 23
Prospectus supplement
5:07pm
. Our mission is to lead a revolution in oncology therapy by delivering its innovative and targeted intra-arterial (IA) delivery of chemotherapy
8-K
EX-99.1
RNXT
RenovoRx Inc
15 May 23
RenovoRx Reports First Quarter 2023 Financial Results and Operational Highlights
8:30am
-stage biopharmaceutical company with a vision to disrupt the current paradigm of cancer treatment. Our mission is to lead a revolution in oncology
8-K
EX-99.1
1r8n ohvbjolbw
27 Apr 23
Departure of Directors or Certain Officers
8:30am
8-K
EX-99.1
235ukjf29qwb9hx940vu
3 Apr 23
RenovoRx, Inc. Announces $5 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:45pm
424B5
l76 ou0eaotwrv
3 Apr 23
Prospectus supplement for primary offering
9:00am
8-K
EX-99.1
3784 q3qj
14 Nov 22
RenovoRx Reports Third Quarter 2022 Financial Results
8:45am
8-K
EX-99.1
9c95c8
19 Sep 22
RenovoRx Appoints Angela Gill Nelms as Chief Operating Officer
8:45am
8-K
EX-99.1
6tocf3xzhf60nbq5maxd
19 Jul 22
RenovoRx Appoints James Ahlers as Chief Financial Officer
8:45am
- Prev
- 1
- Next